Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)

被引：0

作者：

Chon, H. ^{[1
]}

Song, Y. S. ^{[2
]}

Yang, H. ^{[3
]}

Kim, I. ^{[4
]}

Hye-Young, K. ^{[5
]}

Lee, W. S. ^{[6
]}

Sang, Y. B. ^{[7
]}

Kim, C. ^{[8
]}

机构：

[1] Bundang Cha Med Ctr, Med Oncol, Seongnam, South Korea

[2] CHA Bundang Med Ctr, Div Endocrinol & Metabolsim, Seongnam, South Korea

[3] Bundang Cha Med Ctr, Oncol, Seongnam, South Korea

[4] Inje Univ, Med Oncol, Haeundae Paik Hosp, Busan, South Korea

[5] Ulsan Univ Hosp, Med oncol, Ulsan, South Korea

[6] Bundang Cha Med Ctr, Lab Translat Immunooncol, Seongnam, South Korea

[7] CHA Bundang Med Ctr, Hematol & Oncol, Seongnam, South Korea

[8] Bundang Cha Med Ctr, Dept Med Oncol, Seongnam, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

基金：

新加坡国家研究基金会;

关键词：

D O I：

10.1016/j.annonc.2023.09.2137

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

993P

引用

页码：S611 / S611

页数：1

共 50 条

[21] Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"
Lee, Sung Hwan
Yim, Sun Young
Kim, Ji Hoon
Lee, Sunyoung S.
Kaseb, Ahmed
Wei, Peng
Lee, Ju-Seog
CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
[22] Atezolizumab (ATEZO) plus Bevacizumab ( BEV) vs Sorafenib (SOR) in Patients (PTS) with Unresectable Hepatocellular Carcinoma (HCC): Phase 3 Results from Imbrave150
Galle, Peter R.
Cheng, Ann-Lll
Qin, Shukui
Ikeda, Masafumi
Ducreux, Michel
Zhu, Andrew
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Verret, Wendy
Xu, Derek
Hernandez, Sairy
Liu, Juan
Shao, Hui
Mulla, Sohail
Lim, Hy
Finn, Richard
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 220 - 220
[23] Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
Li, Daneng
Toh, Han Chong
Merle, Philippe
Tsuchiya, Kaoru
Hernandez, Sairy
Verret, Wendy
Nicholas, Alan
Kudo, Masatoshi
LIVER CANCER, 2022, 11 (06) : 558 - 571
[24] IMbrave150: exploratory efficacy and safety results of atezolizumab plus bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
Salem, Riad
Galle, Peter
Finn, Richard
Ducreux, Michel
Singal, Amit
Nicholas, Alan
Hernandez, Sairy
Verret, Wendy
Merle, Philippe
Zhu, Andrew
JOURNAL OF HEPATOLOGY, 2021, 75 : S246 - S247
[25] Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
Kudo, Masatoshi
Tsuchiya, Kaoru
Shao, Yu-Yun
Finn, Richard S.
Galle, Peter R.
Ducreux, Michel
Cheng, Ann-Lii
Yamashita, Tatsuya
Koga, Hironori
Take, Ryosuke
Yamada, Kyoko
Asakawa, Takashi
Nakagawa, Yuki
Ikeda, Masafumi
LIVER CANCER, 2024, 13 (04) : 401 - 412
[26] Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
Tada, Toshifumi
Kumada, Takashi
Hiraoka, Atsushi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Nishikawa, Hiroki
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Koshiyama, Yuichi
Toyoda, Hidenori
Ogawa, Chikara
Hatanaka, Takeshi
Kakizaki, Satoru
Kawata, Kazuhito
Ohama, Hideko
Tada, Fujimasa
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Nishimura, Takashi
Imai, Michitaka
Kosaka, Hisashi
Naganuma, Atsushi
Matono, Tomomitsu
Aoki, Tomoko
Kuroda, Hidekatsu
Yata, Yutaka
Koizumi, Yohei
Nakamura, Shinichiro
Enomoto, Hirayuki
Kaibori, Masaki
Hiasa, Yoichi
Kudo, Masatoshi
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (02) : 233 - 245
[27] Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini
Mara Persano
Toshifumi Tada
Goki Suda
Shigeo Shimose
Masatoshi Kudo
Jaekyung Cheon
Fabian Finkelmeier
Ho Yeong Lim
José Presa
Gianluca Masi
Changhoon Yoo
Sara Lonardi
Fabio Piscaglia
Takashi Kumada
Naoya Sakamoto
Hideki Iwamoto
Tomoko Aoki
Hong Jae Chon
Vera Himmelsbach
Tiziana Pressiani
Margarida Montes
Caterina Vivaldi
Caterina Soldà
Atsushi Hiraoka
Takuya Sho
Takashi Niizeki
Naoshi Nishida
Christoph Steup
Masashi Hirooka
Kazuya Kariyama
Joji Tani
Masanori Atsukawa
Koichi Takaguchi
Ei Itobayashi
Shinya Fukunishi
Kunihiko Tsuji
Toru Ishikawa
Kazuto Tajiri
Hironori Ochi
Satoshi Yasuda
Hidenori Toyoda
Chikara Ogawa
Takashi Nishimura
Takeshi Hatanaka
Satoru Kakizaki
Noritomo Shimada
Kazuhito Kawata
Fujimasa Tada
Hideko Ohama
Targeted Oncology, 2023, 18 : 221 - 233
[28] Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Qin, Shukui
Ren, Zhenggang
Feng, Yin-Hsun
Yau, Thomas
Wang, Baocheng
Zhao, Haitao
Bai, Yuxian
Gu, Shanzhi
Li, Lindong
Hernandez, Sairy
Xu, Derek-Zhen
Mulla, Sohail
Wang, Yifan
Shao, Hui
Cheng, Ann Lii
LIVER CANCER, 2021, 10 (04) : 296 - 308
[29] Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Kudo, Masatoshi
Finn, Richard S.
Cheng, Ann-Lii
Zhu, Andrew X.
Ducreux, Michel
Galle, Peter R.
Sakamoto, Naoya
Kato, Naoya
Nakano, Michitaka
Jia, Jing
Vogel, Arndt
LIVER CANCER, 2023, 12 (05) : 479 - 493
[30] Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series
Ichimura, Takenori
Ichikura, Daisuke
Hinata, Miwa
Hida, Noriko
Baba, Toshiyuki
SAGE OPEN MEDICAL CASE REPORTS, 2023, 11

← 1 2 3 4 5 →